Priyanka Iyer, M.B.B.S
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Armed Forces Medical College, Pune Maharashtra University of Health Sciences, Pune, IND, MBBS, Medicine |
Postgraduate Training
| 2017-2018 | Research Fellowship, Endocrinology, Diabetes and Metabolism, Baylor College of Medicine/The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2015-2017 | Clinical Fellowship, Endocrinology, Diabetes and Metabolism, Baylor College of Medicine/The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2014-2015 | Chief Resident, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, MD |
| 2012-2014 | Clinical Residency, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, MD |
| 2011-2012 | Clinical Internship, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, MD |
Board Certifications
| 2017 | American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism |
| 2014 | American Board of Internal Medicine |
Experience & Service
Institutional Committee Activities
Member, Anaplastic Thyroid Cancer (ATC) Planning Clinic, 2016 - 2018
Member, ATC/DTC Translational Research Working Group, 2016 - 2018
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Qin Y, Wang JR, Wang Y, Iyer PC, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid(8):1235-1243, 2021. PMID: 33599171.
- Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer 28(7):419-431, 2021. PMID: 33890870.
- Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule- Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn BG, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer PC, Cabanillas ME. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E- mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036-1043, 2019. PMID: 31319771.
- Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E cell-free DNA as a biomarker in the management of anaplastic thyroid carcinoma. JCO Precision Oncol(2):1-11, 2018. PMID: 35135166.
- Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid(10):1243-1251, 2018. PMID: 30132401.
- Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and immune- directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7):945-951, 2018. PMID: 29742974.
- Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):68, 2018. PMID: 29996921.
- Chavez AAL, Iyer PC, Cazacu IM, Cabanillas ME, Rashid A, Bhutani MS. Anaplastic Thyroid Carcinoma with Gastric Metastasis. Curr Health Sci J 44(3):294-298, 2018. e-Pub 2018. PMID: 30647951.
- Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28(1):79-87, 2018. PMID: 29161986.
Invited Articles
- Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000 Faculty Rev 7(87), 2018. e-Pub 2018. PMID: 31583077.
Book Chapters
- Iyer PC, Abadilla K, Dobs A. Medical disorders and complications of alcohol and other drugs, pain and addiction. In: Textbook of Addiction Treatment: International Perspectives. Springer Milan Heidelberg New York Dordrecht London, 1811-1830, 2015.
Grant & Contract Support
| Title: | Circulating BRAF V600E cell free DNA (cfDNA) as a biomarker of response in the management of Anaplastic Thyroid Carcinoma |
| Funding Source: | Endocrine Fellows Foundation |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified May 07, 2024